Arons & Arons, LLC. Announces Investigation on Behalf of Endo International plc Investors
June 09 2017 - 1:54PM
Business Wire
The Law Firm of Arons & Arons, LLC. has initiated an
investigation of Endo International plc (“Endo” or the “Company”)
(NASDAQ: ENDP) on behalf of the company’s investors for possible
violations of federal securities law.
Endo investors who would like to discuss this investigation and
their legal options should contact Arons & Arons, LLC. (Jeffrey
S. Arons, Esq.) at (973) 762-0795, or email us at
info@aronslaw.net.
Endo reformulated Opana ER, an opiod painkiller in 2012.
However, the U.S. Food and Drug administration has deemed Opana ER
too dangerous for distribution. On June 8, 2017, the U.S. Food and
Drug Administration (the “FDA”) instructed Endo to pull Opana ER
off the U.S. market. According to the FDA the drug was pulled “due
to the public health consequences of abuse”.
As a result, shares of Endo have fallen over 14% during intraday
trading on June 9, 2017.
If you are an investor in Endo, or have information pertaining
to this investigation, you are encouraged to contact Arons &
Arons, LLC. (Jeffrey Arons, Esq.) at (973) 762-0795 or email us at
info@aronslaw.net.
Arons & Arons, LLC, is a family oriented firm, that provides
representation for individuals, including investors who have
been victimized by securities fraud. Our attorneys understand the
financial and emotional trauma that securities fraud can cause, and
we are relentless in our efforts to hold corporate wrongdoers
accountable and obtain compensation for our clients. For over 30
years our attorneys have provided personal, accessible, and
effective legal representation for our clients.
This press release may be considered Attorney Advertising in
some jurisdictions under applicable laws and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170609005701/en/
Arons & Arons, LLC.Jeffrey Arons, Esq.,
973-762-0795info@aronslaw.net
Endo (NASDAQ:ENDP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endo (NASDAQ:ENDP)
Historical Stock Chart
From Apr 2023 to Apr 2024